Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma

Blood(2021)10.1182/blood.2020008136Source: DataRank Database

Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma is a research paper published in Blood (2021). On theSindex it has a DataRank of 0. It has been cited 49 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access49 citations

Download PDF

Cite:

Linked data & code

geo nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)OA: bronzeTopics (42)IDs (PubMed, PMC)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Carmen Mecca ORCID,Qi Wang ORCID,Chiara Ambrogio ORCID,Inês Mota ORCID,Nina Prokoph ORCID

Live enrichment

PubMed:34657149 PMC:PMC8814675

NCI NIH HHS

Grant: R01 CA196703

European Commission

Grant: 675712

ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer

National Institutes of Health

Grant: 5R01CA196703-09

Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma

bronze

publisherhttps://ashpublications.org/blood/article-pdf/139/5/717/1881289/bloodbld2020008136.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8814675

https://doi.org/10.1182/blood.2020008136

https://dx.doi.org/10.17863/cam.76335

https://pubmed.ncbi.nlm.nih.gov/34657149

Fields of Study

03 medical and health sciences0302 clinical medicineAnaplastic Lymphoma KinaseAnimalsAntineoplastic AgentsCell Line, TumorCrizotinibHumansLymphoma, Large-Cell, AnaplasticMice, Inbred NODMice, SCIDProtein Kinase InhibitorsProtein Tyrosine Phosphatase, Non-Receptor Type 1Protein Tyrosine Phosphatase, Non-Receptor Type 2Mice

MeSH Terms

Cell Line, TumorAnimalsMice, Inbred NODHumansMiceMice, SCIDAntineoplastic AgentsProtein Kinase InhibitorsLymphoma, Large-Cell, AnaplasticProtein Tyrosine Phosphatase, Non-Receptor Type 1Protein Tyrosine Phosphatase, Non-Receptor Type 2CrizotinibAnaplastic Lymphoma Kinase

Keywords

Protein Tyrosine Phosphatase, Non-Receptor Type 1Protein Tyrosine Phosphatase, Non-Receptor Type 2anaplastic large cell lymphoma, ALK+, TKIs, STAT3, PTPN1, Tyrosine phosphatases;Antineoplastic AgentsMice, SCIDMiceCrizotinibMice, Inbred NODCell Line, TumorAnimalsHumansLymphoma, Large-Cell, AnaplasticAnaplastic Lymphoma KinaseProtein Kinase Inhibitors

Sustainable Development Goals

SDG 3: 3. Good health